$4.76
+0.01 (+0.21%)
Open$4.72
Previous Close$4.75
Day High$4.83
Day Low$4.66
52W High$6.95
52W Low$3.27
Volume—
Avg Volume117.2K
Market Cap246.54M
P/E Ratio—
EPS$-1.18
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+509.0% upside
Current
$4.76
$4.76
Target
$28.99
$28.99
$18.54
$28.99 avg
$38.99
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 25.42M | 21.70M | 271.86M |
| Net Income | -61,091,414 | -46,937,231 | 13.33M |
| Profit Margin | -240.3% | -228.3% | 4.9% |
| EBITDA | -65,540,547 | -53,153,081 | 20.13M |
| Free Cash Flow | — | — | 11.27M |
| Rev Growth | +17.1% | +17.1% | -6.6% |
| Debt/Equity | — | — | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |